Innate Pharma S.A.
IPHYF
$1.50
$0.139.29%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -71.85% | -72.58% | -78.75% | -80.47% | -74.11% |
| Total Other Revenue | -4.04% | -6.55% | -17.02% | -23.71% | -30.15% |
| Total Revenue | -41.79% | -43.31% | -58.49% | -61.84% | -64.09% |
| Cost of Revenue | 10.14% | 7.25% | -25.58% | -31.59% | -7.70% |
| Gross Profit | -36.83% | -33.25% | 1.31% | 9.27% | -379.17% |
| SG&A Expenses | 3.74% | 1.02% | 7.48% | -1.19% | 9.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.18% | 5.34% | -17.39% | -24.05% | -2.97% |
| Operating Income | -23.56% | -20.32% | -1.89% | 6.33% | -103.85% |
| Income Before Tax | -23.02% | -19.80% | 9.12% | 16.45% | -163.39% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -23.02% | -19.80% | 9.12% | 16.45% | -163.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.02% | -19.80% | 9.12% | 16.45% | -163.39% |
| EBIT | -23.56% | -20.32% | -1.89% | 6.33% | -103.85% |
| EBITDA | -25.33% | -22.05% | -3.37% | 4.97% | -151.78% |
| EPS Basic | -8.33% | -5.50% | 15.47% | 22.26% | -161.45% |
| Normalized Basic EPS | -8.39% | -5.45% | 15.44% | 22.33% | -161.08% |
| EPS Diluted | -8.33% | -5.50% | 14.93% | 21.87% | -161.45% |
| Normalized Diluted EPS | -8.39% | -5.45% | 15.44% | 22.33% | -161.08% |
| Average Basic Shares Outstanding | 13.56% | 13.56% | 7.50% | 7.50% | 0.80% |
| Average Diluted Shares Outstanding | 13.56% | 13.56% | 7.50% | 7.50% | 0.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |